Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

(NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the ...

Hepatic resection and transplantation remain the standard curative therapies for hepatocellular carcinoma ... liver disease are best served by transplant evaluation; however, the best treatment ...

liver transplant is the treatment of choice Nonsurgical treatments (PEI, RFA, and TACE) are employed to minimize drop-out from the transplant waiting list, which nevertheless occurs in 20% of ...

The then 36-year-old courtroom bailiff received Milwaukee County General Hospital's 500th kidney transplant. After suffering from a kidney infection for a decade and spending months on dialysis ...

This case report details a patient with hepatocellular carcinoma who developed T1DM and DKA following ... his admission to the Department of Hepatobiliary, Pancreatic, and Transplant Surgery at Xi’an ...

Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US). Patterns of ...

Rates and risk factors for recurrence of hepatocellular carcinoma after initial complete remission in response to transcatheter arterial chemoembolization: A systematic review and meta-analysis. This ...

AI decision support system non-homogenously influences clinical decisions in dynamic treatment regimen, as it depends on several factors including prior knowledge, preference, disease type ...

This valuable study investigated the role of PLECTIN, a cytoskeletal crosslinker protein, in hepatocellular carcinoma development and progression. Using a liver-specific Plectin knockout mouse model, ...